Mounjaro vs Soliqua

Drug comparison

Last updated 2026-05-28 15:46 UTC

Mounjaro (active ingredient: tirzepatide) and Soliqua (active ingredient: lixisenatide) are both injectable medications for type 2 diabetes, made by Eli Lilly and Sanofi respectively. Both are taken as subcutaneous injections, but Mounjaro is a once-weekly treatment, while Soliqua is taken once daily.

AI summary of the sources below.

	Mounjaro	Soliqua
Active ingredient	tirzepatide	lixisenatide
Manufacturer	eli-lilly	sanofi
Route	subcutaneous injection	subcutaneous injection
FDA-approved for	type 2 diabetes	type 2 diabetes
Label updated	2026-04-22	2026-03-18

Compare full details on the Mounjaro and Soliqua pages.